Philadelphia, May 28, 2019 - A genome-wide association study has identified five new genetic risk loci that can pass on risk for harmful alcohol use from parents to children, and confirmed one previously identified risk locus. The findings were published in Biological Psychiatry, published by Elsevier.
The risk variants associated with maximum habitual alcohol use were identified using data from the Million Veteran Program (MVP), a study creating a database of genetic and health information of US military veterans. Habitual alcohol use can lead to alcohol dependence and is connected to many health problems. The findings provide insight into the role of genetics in this behavior.
"Even in this era of large samples for genetics studies, the MVP sample stands out: it is one of the largest samples collected so far using the same questions to assess alcohol use; and it includes many socioeconomically disadvantaged individuals and people of non-European descent, who are underrepresented in most other such studies," said first author Joel Gelernter, MD, Yale University School of Medicine.
This diversity of the sample allowed the researchers to divide nearly 144,000 participants based on African or European ancestry and included the largest single African-ancestry sample studied thus far for the genetics of alcohol. Integrating the unique genetic histories of the African-American and European-American subpopulations in a meta-analysis greatly improved the genetic mapping precision of the analysis. Using this approach, Dr. Gelernter and colleagues identified a strong association of maximum habitual alcohol use with a new risk locus, CRHR1, corticotropin-releasing hormone receptor 1.
"Habitual excessive alcohol consumption is the most difficult to treat because of its compulsive nature. This study provides new insights into mechanisms that may drive this behavior. Interestingly, this study implicates CRHR1, a gene previously implicated in stress response. By implicating this gene, this study may suggest a link between the propensity for a heightened stress response and the risk for habitual alcohol use," said John Krystal, MD, Editor of Biological Psychiatry.
When the subgroups of differing ancestry were analyzed separately, the locus most strongly associated with maximum habitual alcohol use, gene ADH1B, was the same in both populations. This gene has been flagged in previous genome-wide studies, confirming its importance in genetic risk for many traits related to alcohol use and abuse. Three new loci were also identified in the European-American group, including CRHR1.
The alcohol-related genetic loci--taken as a whole across the genome--were associated with many other traits, including tobacco smoking, socioeconomic status, physical activity, and other health complications, highlighting the pervasive effects of habitual alcohol use on many other aspects of health and behavior.
"This study demonstrates the tremendous utility of the MVP for discovery of genetic variants associated with excessive alcohol use and with other health-relevant problems and disease states. The MVP as currently analyzable is only about a third of its eventual size, so we may confidently predict much more from it in future," said senior author Murray Stein, MD, University of California San Diego.
Notes for editors
The article is "Genomewide Association Study of Maximum Habitual Alcohol Intake in >140,000 US European- and African-American Veterans Yields Novel Risk Loci," by Joel Gelernter, Ning Sun, Renato Polimanti, Robert Pietrzak, Daniel F. Levey, Qiongshi Lu, Yiming Hu, Boyang Li, Krishnan Radhakrishnan, Mihaela Aslan, Kei-Hoi Cheung, Yuli Li, Nallakkandi Rajeevan, Fred Sayward, Kelly Harrington, Quan Chen, Kelly Cho, Jacqueline Honerlaw, Saiju Pyarajan, Todd Lencz, Rachel Quaden, Yunling Shi, Haley Hunter-Zinck, J. Michael Gaziano, Henry R. Kranzler, John Concato, Hongyu Zhao, Murray B. Stein, on behalf of the Department of Veterans Affairs Cooperative Studies Program (#575B) and Million Veteran Program (https:/
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at Biol.Psych@sobp.org or +1 214 648 0880. Journalists wishing to interview the authors may contact Joel Gelernter, MD, at firstname.lastname@example.org or Murray B Stein, MD, MPH at email@example.com.
The authors' affiliations and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 6th out of 142 Psychiatry titles and 9th out of 261 Neurosciences titles in the Journal Citations Reports® published by Clarivate Analytics. The 2017 Impact Factor score for Biological Psychiatry is 11.982. http://www.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we're committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. http://www.
Rhiannon Bugno, Editorial Office
+1 214 648 0880